GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,401.20p
   
  • Change Today:
    -36.60p
  • 52 Week High: 2,263.00
  • 52 Week Low: 1,296.00
  • Currency: UK Pounds
  • Shares Issued: 4,094.93m
  • Volume: 10,229,838
  • Market Cap: £57,378m
  • RiskGrade: 129

GSK looks to Burberry for new CFO

By Abigail Townsend

Date: Monday 26 Sep 2022

LONDON (ShareCast) - (Sharecast News) - GSK has named Burberry Group's Julie Brown as its new chief financial officer.
Current incumbent Iain Mackay is retiring, GSK said, and will step down from the role and board in May 2023. Brown, currently chief operating and financial officer of the luxury fashion brand, will join GSK in April 2023.

Emma Walmsley, chief executive, said: "I am absolutely delighted that Julie will be joining the leadership team. Julie is a very experienced CFO with a tremendous understanding of the biopharma sector."

Brown joined Burberry in 2017 from Smith & Nephew, before which she had spent 25 years at Anglo-Swedish drugs group AstraZeneca, including a period as interim chief financial officer.

Mackay joined drug and healthcare giant GlaxoSmithKline in 2019. Earlier this year, the healthcare business was spun off as Haleon, with the remainder of the business rebranded GSK and focused exclusively on prescription drugs and vaccines.

Haleon's £30bn listing was the biggest in London since Glencore's 2011 initial public offering.

Shares in GSK were ahead 2% as trading got underway at 0815 BST, at 1,335.2p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,401.20p
Change Today -36.60p
% Change -2.55 %
52 Week High 2,263.00
52 Week Low 1,296.00
Volume 10,229,838
Shares Issued 4,094.93m
Market Cap £57,378m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.56% below the market average65.56% below the market average65.56% below the market average65.56% below the market average65.56% below the market average
43.33% above the sector average43.33% above the sector average43.33% above the sector average43.33% above the sector average43.33% above the sector average
Price Trend
5.18% below the market average5.18% below the market average5.18% below the market average5.18% below the market average5.18% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
45.24% above the market average45.24% above the market average45.24% above the market average45.24% above the market average45.24% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
51.07% below the market average51.07% below the market average51.07% below the market average51.07% below the market average51.07% below the market average
52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average52.38% below the sector average

What The Brokers Say

Strong Buy 3
Buy 6
Neutral 13
Sell 1
Strong Sell 2
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 23-Feb-23 17-Nov-22
Paid 13-Apr-23 12-Jan-23
Amount 13.75p 13.75p

Trades for 24-Mar-2023

Time Volume / Share Price
17:58 726 @ 1,392.68p
17:58 291 @ 1,392.61p
17:58 147 @ 1,392.60p
17:58 348 @ 1,390.62p
17:58 142 @ 1,390.61p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page